share_log

Needham Reiterates Buy on Cidara Therapeutics, Maintains $3 Price Target

Benzinga ·  Sep 8, 2023 04:17

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment